This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Therapy Choices for Late-Life Depression

Stuart A. Montgomery, M.D.

Published: April 18, 2013

Article Abstract

Late-life depression has a chronic course and is often complicated by coexistent medical conditions, of which anxiety is the most common. Clinical evidence exists for the efficacy of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) in late-life depression. Unlike TCAs, SSRIs benefit from a benign tolerability profile and are not associated with adverse cardiovascular effects, anticholinergic activity, or significant sedative properties. The choice of SSRI for latelife depression should take into account pharmacokinetic differences between SSRIs that confer additional safety and tolerability advantages.


Related Articles

Volume: 2

Quick Links: Depression (MDD)


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...